China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
New favorable policy for TCM industry was released. We analyzed our top picks. Pfizer is in talks to acquire Seagen, but we're conservative about the deal. Haohai actually has entered a vicious circle
Equity Bottom-Up
431 Views, 05 Mar 2023 09:00
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Analytics & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Bond Market Monitor: A Contempt Against Depositors16 Mar 2023
- “Sudden Death” of Silicon Valley Bank (SVB) - The Impact on China Healthcare13 Mar 2023
- China Healthcare Weekly (Mar.10)- Three Conditions to Be Biopharma, Anticipate the Collapse, DS-820112 Mar 2023
- China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological05 Mar 2023
- Shandong Weigao Group Medical Polymer (1066.HK) - As a Holding Platform, Investment Value Is Limited03 Mar 2023
- China Healthcare Weekly (Feb.24) - No. 1 Central Document, 8th National VBP, TCM Formula Granules26 Feb 2023
- Pre-IPO Fangzhou Group - The Business and the Concerns24 Feb 2023
- Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook10 Feb 2023
x